Amphastar (AMPH) Q1 2026 earnings review
Flat Revenues Mask a Severe Profitability Squeeze
Amphastar delivered a zero-growth quarter on the top line ($171.2M), but the real story is a brutal collapse in profitability. Gross margin compressed dramatically to 41.1% (down from 50.0% a year ago), driving a 47% YoY drop in Adjusted Net Income. The margin deterioration was fueled by intense pricing pressure on legacy assets like Glucagon, alongside an unexpected pricing hit to BAQSIMI. While new product launches like Ipratropium Bromide HFA and ongoing competitor shortages kept revenues stable, the underlying earnings quality has severely deteriorated.
🐂 Bull Case
The highly anticipated Ipratropium Bromide HFA (AMP-007) was approved and launched, carrying 180 days of generic exclusivity. Additionally, recently launched products like Albuterol, Iron Sucrose, and Teriparatide drove the 'Other Products' segment up 34% YoY.
Amphastar is successfully capturing market share where competitors are failing. Epinephrine pre-filled syringes and Dextrose saw unit volume increases explicitly driven by ongoing market shortages from other suppliers.
🐻 Bear Case
Gross margin dropped nearly 900 basis points YoY to 41.1%. The company is being squeezed from both sides: lower average selling prices (ASP) on its highest-margin products and increased manufacturing costs from the Rancho Cucamonga facility expansion.
BAQSIMI, which management previously touted as the primary growth engine, reversed into a 15% revenue decline due to severe gross-to-net discount changes. Meanwhile, the Glucagon franchise is in a terminal dive, down 56% YoY.
⚖️ Verdict: 🔴
Bearish. The flat revenue headline is deceptive. A 47% drop in adjusted net income driven by widespread pricing pressure across the most critical product lines indicates a fundamental deterioration in the business mix.
Key Themes
Gross Margin Collapse
Profitability is decelerating rapidly. Gross margin plummeted from 50.0% in 25Q1 to just 41.1% in 26Q1. This was driven by aggressive price competition hitting the company's most lucrative products (BAQSIMI, Glucagon, multi-dose Epinephrine) combined with rising overhead from the Rancho Cucamonga facility expansion. Operating leverage is breaking down as cost of revenues surged 18% despite flat sales.
BAQSIMI Narrative Contradiction
In the 25Q4 earnings call, management painted BAQSIMI as a 'reliable top performer' driving double-digit growth. 26Q1 data directly contradicts this: BAQSIMI sales reversed, falling 15% YoY to $32.4M. Despite higher unit volumes, an $8.0M hit from changes in gross-to-net discounts, chargebacks, and rebates completely erased the growth narrative. This suggests severe pricing concessions were required to move volume.
Accelerating Demise of Glucagon
The legacy Glucagon product is in freefall, shrinking 56% YoY to just $9.2M. Management noted a $6.1M impact from lost volume and a $5.6M impact from price erosion. The market is aggressively shifting toward ready-to-use alternatives, and Amphastar's pricing power here has vanished.
Ipratropium Bromide HFA Approval
The FDA approval and subsequent launch of Ipratropium Bromide HFA provides a critical lifeline. With 180 days of generic drug exclusivity, this product is the company's most viable near-term catalyst to offset legacy portfolio erosion.
Other Products Segment Rescuing Top Line
The 'Other Products' segment was the sole reason total revenues didn't contract. Accelerating 34% YoY to $67.1M, the growth was driven by recent launches like Albuterol (+$2.8M), Iron Sucrose (+$1.4M), and Teriparatide (+$2.2M). This validates the company's R&D engine, though the margin profile of these products appears lower than the legacy assets they are replacing.
Macro Tailwinds: Competitor Shortages
Amphastar continues to benefit from supply chain disruptions affecting its rivals. Epinephrine pre-filled syringes added $4.1M in sales, and Dextrose saw a significant boost strictly due to heightened demand resulting from other supplier shortages in the broader macroeconomic environment.
Proprietary Pipeline Pivot
The company continues to shift capital away from pure generics toward proprietary therapies. R&D spending accelerated 33% YoY, driven by a $2.0M upfront licensing payment for a fully synthetic corticotropin compound (AMP-107), alongside continued investment in insulin and GLP-1 biosimilars.
Other KPIs
Accelerating. Total operating expenses jumped 18% YoY. Research and development saw the sharpest increase (+33% to $26.7M), followed by G&A (+13% to $18.0M) driven by legal expenses and ERP implementation. This spending ramp severely compressed operating income in a flat-revenue environment.
Stable. Despite the severe drop in net income, operating cash flow actually improved from $35.1M in the prior year period. This suggests strong working capital management and cash conversion, providing a buffer to fund the Rancho Cucamonga capacity expansion.
Guidance
Management previously guided for roughly 7-9% top-line growth for the full year 2026. Given that 26Q1 came in at exactly 0% growth, achieving this annual target will require massive acceleration in Q2-Q4. This effectively places immense pressure on the newly launched Ipratropium Bromide HFA to deliver immediately.
Key Questions
BAQSIMI Pricing Floor
BAQSIMI revenue fell 15% due to an $8M impact from chargebacks and rebates. Has the gross-to-net discount profile for this product permanently reset, or was this a one-time adjustment?
Gross Margin Stabilization
With gross margins compressing to 41.1%, down from 47% just last quarter, what is the expected margin floor as Rancho Cucamonga expansion costs persist and legacy high-margin products decline?
Guidance Feasibility
Given the 0% revenue growth in Q1, achieving the previously stated 'mid-to-high single-digit' annual growth implies significant acceleration. What specific revenue contribution is modeled for Ipratropium Bromide HFA to bridge this gap?